Prognostic value of microRNA-21 in epithelial ovarian carcinoma
A protocol for systematic review and meta analysis
Kun Ji, MD\textsuperscript{a}, Xiaohua Wang, MD\textsuperscript{b}, Anqi Zhang, MD\textsuperscript{c}, Hongwei Wen, MD\textsuperscript{d,*}

Abstract
Background: The expression of microRNA-21 has been shown to be associated with the prognosis in patients with malignant tumors. However, its prognostic value in epithelial ovarian carcinoma (EOC) remains controversial. This meta-analysis aimed to synthesize available data to clarify the association between microRNA-21 expression levels and clinical prognosis in EOC patients.

Methods: Eligible literatures were searched from Embase, Google Scholar, PubMed, Web of Science, Medline, Cochrane Library, China Scientific Journal Database, China National Knowledge Infrastructure, Chinese BioMedical Database and Wanfang Database to identify eligible studies. Papers in English or Chinese published from their inception to November 2020 will be included. Methodological quality for each eligible trial will be assessed by using the Newcastle-Ottawa Quality Assessment Scale. Odds ratios or hazards ratios with corresponding 95% confidence intervals were pooled to estimate the prognosis value of microRNA-21 by using Stata 14.0 and Review Manager 5.3 software.

Results: This study will provide a high-quality evidence-based medical evidence of the correlations between microRNA-21 expression and overall survival and disease-free survival.

Conclusion: The findings of this systematic review will show the effect of high expression of microRNA-21 on the prognosis of EOC patients.

Trial registration number: INPLASY2020110064

Abbreviations: DFS = disease-free survival, EOC = epithelial ovarian carcinoma, INPLASY = International Platform of Registered Systematic Review and Meta-Analysis Protocols, OS = overall survival, PRISMA-P = Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols.

Keywords: epithelial ovarian carcinoma, meta-analysis, miRNA-21, prognosis

1. Introduction
Ovarian carcinoma (OC) is the 19th most commonly diagnosed malignancy and the second most common cause of gynecologic cancer death in women (accounts for about 20% of all female reproductive cancers) around the world.\textsuperscript{[1–4]} According to global cancer statistics, about 184,800 deaths occurred worldwide in 2018, ranking the 15th leading cause of tumor-related deaths.\textsuperscript{[1,2]} OC can occur at any age, more common in patients older than 50 years.\textsuperscript{[3–6]} With increasing life-expectancy, the number of cases diagnosed each year is increasing.\textsuperscript{[3–6]} Epithelial ovarian carcinoma (EOC) is the primary type of OC, accounting for more than 90% of total OC.\textsuperscript{[7–11]} Despite the improvement of diagnostic and therapeutic methods in the past decades, the prognosis of EOC remains unsatisfactory.\textsuperscript{[5,6,10,11]} Over 60% to 70% of OC patients are diagnosed at advanced stage, with 5-year survival rates below 45%.\textsuperscript{[9]} Therefore, the development of a novel biological marker for the prognosis prediction of EOC remains urgent.

MicroRNA-21, a member of the microRNA family, is encoded by the MIR21 gene located on chromosome 17q23.2 in humans.\textsuperscript{[12,13]} The mature microRNA-21 is formed from endogenous non-coding RNA molecules with a length of ~22 nucleotides.\textsuperscript{[13]} It can bind with the 3’UTR sequence of messenger RNA (mRNA) to degrade mRNA or inhibit the transcription of mRNA, thereby participating in the biological processes of regulating cell proliferation, apoptosis and innate immunity.\textsuperscript{[11–13]} It may be involved as an oncogene or tumor suppressor gene in the occurrence and development of various tumors including EOC.\textsuperscript{[13–18]} Previous studies reported that microRNA-21 is
microRNA-21 on the prognosis of EOC patients.

This study will try to explore the effect of high expression of microRNA-21 with poor prognosis in patients with EOC? Whether the high expression of microRNA-21 is in association with survival in patients with EOC? To solve the issue, our study will used meta-analysis to evaluate the association between microRNA-21 and survival in patients with EOC has not yet been systematically evaluated. Although several studies have investigated the potential value of microRNA-21 expression in the prognosis prediction and diagnosis of EOC, the exact association between microRNA-21 and survival in patients with EOC.

1.1. Review question
Whether the high expression of microRNA-21 is in association with poor prognosis in patients with EOC?

1.2. Study aim/Objective
This study will try to explore the effect of high expression of microRNA-21 on the prognosis of EOC patients.

2. Methods
2.1. Study registration
This meta-analysis protocol is based on the Preferred Reporting Items for Systematic Reviews and meta-analysis Protocols (PRISMA-P) statement guidelines. The PRISMA-P checklist for the protocol is provided in the PRISMAP-checklist. The protocol of the systematic review has been registered on the International Platform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY). The registration number was INPLASY2020110064. This meta-analysis is a secondary research which based on some previously published data. Therefore, the ethical approval or informed consent was not required in this study.

2.2. Search strategy
The retrieval strategy will be created based on discussion of all the researchers on the basis of the Cochrane handbook guidelines. The plan searched terms are as follows: “ovarian carcinoma” or “epithelial ovarian carcinoma” or “oophoroma” or “OC” or “EOC” and “microRNA-21” or “miR-21” and “prognostic” or “survival”. The detailed sample of search strategy for PubMed database is shown in Table 1. Similar search strategies will be modified and used for the other databases.

2.3. Information sources
Electronic databases including Embase, Google Scholar, PubMed, Web of Science, Medline, Cochrane Library, China Scientific Journal Database, China National Knowledge Infrastructure, Chinese BioMedical Database and Wanfang Database, will be systematically searched for eligible literatures from their inception to November 2020. Language is limited with English and Chinese.

2.4. Eligibility criteria
2.4.1. Types of studies. All available controlled trials that assessed the effect of high expression of microRNA-21 on overall survival (OS) and disease-free survival (DFS) of patients diagnosed with EOC will be included in this systematic review; The included studies should provide the relationship between miRNA-21 expression and clinical pathological characteristics.

2.4.2. Types of participants. Patients must be diagnosed with EOC based on pathology and histology. No restrictions regarding age, gender, racial, region, education and economic status in this analysis. Patients with other malignancies are not included.

2.4.3. Types of interventions. In the experimental group, serum microRNA-21 expression levels were detected in all EOC patients confirmed by histopathology.

2.4.4. Comparator. In the control group, the expression levels of serum microRNA-21 were detected in normal participants.

2.4.5. Exclusion criteria. Articles without sufficient available data, animal experiments, case reports and series, literature reviews, meta-analysis, letters, conference abstract, and other unrelated studies will be all excluded from analysis.

2.5. Types of outcome measures
(1) Overall survival (OS, which is defined as the time from the date of randomization to death from any cause);
(2) DFS, which is the time from date of random assignment to date of recurrence or death;
(3) Hazard ratios with corresponding 95% confidence intervals will be extracted from trials or be estimated from Kaplan-Meier survival curves by established methods.[25]

2.6. Study selection and data extraction

2.6.1. Study selection. Endnote X7 software will be used for literature managing and records searching. Two experienced authors (Kun Ji and Xiaohua Wang) will be reviewed independently to identify potential trials by assessing the titles and abstracts. The full text will be further reviewed to determine potential eligible studies. A PRISMA-compliant flow chart (Fig. 1) will be used to describe the selection process of eligible trials. Excluded studies and reasons for exclusion will be recorded. Disagreements between the 2 researchers will be resolved by consensus or by a third independent investigator (Anqi Zhang).

2.6.2. Data extraction. Two investigators (Kun Ji and Xiaohua Wang) will be responsible for the data extraction independently. Information extracted from eligible literatures is shown in Table 2. When any data are missing or insufficient, we will contact original authors by using email. If the data is not available, we will only analyze the currently available data and discuss its potential impact.

2.7. Risk of bias assessment

Two experienced authors (Kun Ji and Xiaohua Wang) will assess the risk of bias for each eligible study by using the Newcastle-
2.11.1. Publication bias analysis.

Sensitivity analyses. A summary table will report the results of the elimination method to assess the reliability and robustness of the aggregation results. Sensitivity analysis of each parameter was carried out by 1-by-1 elimination method and survival data source. If the included studies are ≥7 were judged to be of higher quality. Any disagreements will be resolved via discussion with a third researcher (Anqi Zhang).

2.11.2. Evidence evaluation.

Sensitivity analysis of each parameter was carried out by 1-by-1 elimination method to assess the reliability and robustness of the aggregation results. A summary table will report the results of the sensitivity analyses.

2.8. Statistical analysis

Stata 14.0 (Stata Corp., College Station, TX, USA) and Review Manager 5.3 (Nordic Cochran Centre, Copenhagen, Denmark) statistical software were used for statistical analyses. Cochran’s Q and Higgins I² statistic were used to assess heterogeneity among the included clinical trials. P < .1 for the Chi² statistic or an I² > 50% will be considered as showing considerable heterogeneity. A fixed effect model will be used to calculate the outcomes when statistical heterogeneity is absent; otherwise, the random effects model will be used for analysis. Odds ratio or hazard ratios with corresponding 95% confidence intervals was used to evaluate the relationship between microRNA-21 expression and OS and DFS.

2.9. Subgroup analysis

Subgroup analysis will only be performed if sufficient clinical data is available. It will be conducted to explore the source of heterogeneity based on different race, EOC stages, microRNA-21 detection method, and survival data source.

2.10. Sensitivity analysis

Sensitivity analysis of each parameter was carried out by 1-by-1 elimination method to assess the reliability and robustness of the aggregation results. A summary table will report the results of the sensitivity analyses.

2.11. Additional analysis

2.11.1. Publication bias analysis. If the included studies are sufficient (≥10 trials), we will detect publication biases of included trials using funnel plots, Begg’s and Egger regression test. If publication bias existed, a trim-and-fill method should be applied to adjust the pooled odds ratio.

2.11.2. Evidence evaluation. The guidelines of the Grading of Recommendations, Assessment, Development, and Evaluation will be used to assess the quality of evidence and the strength of the main result recommendations.

2.12. Dissemination

We will disseminate the results of this systematic review by publishing the manuscript in a peer-reviewed journal or presenting the findings at a relevant conference.

3. Discussion

Although the diagnosis and treatment methods for EOC has been greatly developed in recent decades, its 5-year survival rate still not been significantly improved. Therefore, finding biomarkers with high specificity and high sensitivity has important clinical significance for the prognosis of EOC. MicroRNA-21 is overexpressed in many malignant tumors and has been implicated in tumorigenesis. Accumulating evidence supports a central role for the microRNA-21 in EOC initiation, progression, and chemoresistance. Báez-Vega et al. found that the expression of microRNA-21 in EOC serum is remarkably higher than that in non-EOC serum. Similar results were obtained in studies by Chan et al. and Xu et al. indicating that increased serum microRNA-21 expression was correlated with advanced EOC stage, high tumor grade, and shortened OS. All these findings indicate that serum microRNA-21 may serve as a novel prognostic marker, and can be used as a therapeutic target for the treatment of EOC. All in all, we hope that this meta-analysis will provide more accurate and objective evidence for the relationship between microRNA-21 expression and prognosis in EOC patients.

The systematic review will also have some limitations. Language bias may exist due to the limitation of English and Chinese studies. In addition, the detection method of microRNA-21 and patient age, tumor stage may be different among the included trials. Therefore, there may be a risk of heterogeneity.

Author contributions

Conceptualization: Hongwei Wen and Kun Ji
Data curation: Kun Ji and Xiaohua Wang
Formal analysis: Kun Ji, Xiaohua Wang and Anqi Zhang
Funding acquisition: Anqi Zhang
Investigation: Kun Ji, Xiaohua Wang and Anqi Zhang
Methodology: Kun Ji, Xiaohua Wang and Anqi Zhang
Project administration: Hongwei Wen
Resources: Hongwei Wen and Kun Ji
Software: Hongwei Wen and Kun Ji
Supervision: Hongwei Wen and Kun Ji
Validation: Hongwei Wen and Anqi Zhang
Visualization: Kun Ji and Xiaohua Wang
Writing – original draft: Kun Ji and Xiaohua Wang
Writing – review & editing: Hongwei Wen and Anqi Zhang

References

[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.
[2] Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 2019;144:1941–53.
[3] Roest MA, Evans P. Ovarian cancer: an overview. Am Fam Physician 2009;80:609–16.
[4] Stewart C, Ralyea C, Lockwood S. Ovarian cancer: an integrated review. Semin Oncol Nurs 2019;35:151–6.
[5] Orr B, Edwards RP. Diagnosis and treatment of ovarian cancer. Hematol Oncol Clin North Am 2018;32:943–64.
[6] Rooth C. Ovarian cancer: risk factors, treatment and management. Br J Nurs 2013;22:523–30.
[7] Lou Y, Yang X, Wang F, et al. MicroRNA-21 promotes the cell proliferation, invasion and migration abilities in ovarian epithelial carcinomas through inhibiting the expression of PTEN protein. Int J Mol Med 2010;26:819–27.
[8] Lheureux S, Gourley C, Vergote I, et al. Epithelial ovarian cancer. Lancet Oncol 2019;20:326–37.
[9] Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol 2017;41:1–30.
[10] Corrado G, Salutari V, Palluzzi E, et al. Optimizing treatment in recurrent epithelial ovarian cancer. Expert Rev Anticancer Ther 2017;17:1147–58.
[11] Jessmon P, Boulanger T, Zhou W, et al. Epidemiology and treatment patterns of epithelial ovarian cancer. Expert Rev Anticancer Ther 2017;17:427–37.
[12] Hirata Y, Mura N, Yanihara N, et al. MicroRNA-21 is a candidate driver gene for 1q23-25 amplification in ovarian clear cell carcinoma. BMC Cancer 2014;14:799.
[13] Zheng W, Zhao J, Tao Y, et al. MicroRNA-21: a promising biomarker for the prognosis and diagnosis of non-small cell lung cancer. Oncol Lett 2018;16:2777–82.
[14] Zhang W, Wei L, Luo R, et al. The value of microRNA-21 as a biomarker for the prognosis of lung cancer: a protocol for systematic review and meta-analysis. Medicine 2020;99:e21483.
[15] Zhang W, Chen J, He G, et al. Impact of mirna-21 on survival prognosis of pancreatic cancer: a protocol for systematic review and meta-analysis. Medicine 2020;99:e22045.
[16] Paliwal N, Vashist M, Chauhan M. Evaluation of miR-22 and miR-21 as diagnostic biomarkers in patients with epithelial ovarian cancer. J Biotech 2020;10:142.
[17] Xu YZ, Xi QH, Ge WL, et al. Identification of serum microRNA-21 as a biomarker for early detection and prognosis in human epithelial ovarian cancer. Asian Pac J Cancer Prev 2013;14:1057–60.
[18] Chan JK, Blansit K, Kiet T, et al. The inhibition of miR-21 promotes apoptosis and chemosensitivity in ovarian cancer. Gynecol Oncol 2014;132:739–44.
[19] Mahmoud EH, Fawzy A, A Elshimy RA. Serum microRNA-21 negatively relates to expression of programmed cell death-4 in patients with epithelial ovarian cancer. Asian Pac J Cancer Prev 2018;19:33–8.
[20] Cappelletto R, Tinazzi A, Giurici T, et al. Programmed cell death 4 and microRNA 21 inverse expression is maintained in cells and exosomes from ovarian serous carcinoma effusions. Cancer Cytopathol 2014;122:685–93.
[21] Hao B, Zhang J. miRNA-21 inhibition suppresses the human epithelial ovarian cancer by targeting PTEN signal pathway. Saudi J Biol Sci 2019;26:2026–9.
[22] Yu X, Chen Y, Tian R, et al. miRNA-21 enhances chemoresistance to cisplatin in epithelial ovarian cancer by negatively regulating PTEN. Oncol Lett 2017;14:1807–10.
[23] Li J, Jiang K, Zhao F. Icarin regulates the proliferation and apoptosis of human ovarian cancer cells through microRNA-21 by targeting PTEN, RECK and Bcl-2. Oncol Rep 2013;33:2829–36.
[24] Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015;350:g7647.
[25] Tierney JF, Stewart LA, Gherzi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16.
[26] Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010;25:603–5.
[27] Jackson D, White IR, Riley RD. Quantifying the impact of between-study heterogeneity in multivariate meta-analyses. Stat Med 2012;31:3805–20.
[28] Lin L, Chu H. Quantifying publication bias in meta-analysis. Biometrics 2018;74:785–94.
[29] Báez-Vega PM, Echevarría Vargas IM, Valiyeva F, et al. Targeting miR-375 as a novel treatment for the prognosis of lung cancer: a protocol for systematic review and meta-analysis. Medicine 2020;99:e21483.
[30] Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis: detection, assessment and adjustment for publication bias. Biometrics 1994;50:1088–101.
[31] Bogd C, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088–101.
[32] Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–34.
[33] Yu X, Chen Y, Tian R, et al. miRNA-21 enhances chemoresistance to cisplatin in epithelial ovarian cancer by negatively regulating PTEN. Oncol Rep 2013;33:2829–36.
[34] Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analyses. Biometrics 2000;56:455–63.
[35] Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924–6.
[36] Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015;350:g7647.
[37] Jackson D, White IR, Riley RD. Quantifying the impact of between-study heterogeneity in multivariate meta-analyses. Stat Med 2012;31:3805–20.
[38] Lin L, Chu H. Quantifying publication bias in meta-analysis. Biometrics 2018;74:785–94.
[39] Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–34.